Cizumab (Bevacizumab 400mg) Injection | Avastin Alternative | Used to Treat Colon, Lung, Brain, Ovarian, Kidney & Cervical Cancers
Cizumab (Bevacizumab 400mg) Injection is a targeted cancer therapy used in the treatment of various cancers including colorectal, lung, cervical, and kidney cancer. It works by blocking the growth of new blood vessels that supply tumours (anti-angiogenesis), helping to slow or stop cancer progression. It is administered intravenously under the supervision of a qualified healthcare professional. Bevacizumab, commonly known by its brand name Avastin, is a monoclonal antibody medication designed to inhibit angiogenesis—the formation of new blood vessels.
Product Overview
Cizumab 400mg Injection is a potent targeted therapy and a recombinant humanized monoclonal antibody. Cizumab 400mg Injection contains Bevacizumab, a specialized angiogenesis inhibitor used in the treatment of various types of advanced and metastatic cancers. By blocking the growth of new blood vessels that provide oxygen and nutrients to tumors, Cizumab effectively slows down or stops tumor progression. This anticancer injection is typically used in combination with chemotherapy to improve survival rates and patient outcomes in complex oncology cases.
Product Composition
- Bevacizumab: 400 mg (Active Ingredient)
- Concentration: 25 mg/mL
- Formulation: Sterile, preservative-free solution for intravenous infusion
- Buffer Ingredients: Trehalose dihydrate, sodium phosphate, and polysorbate 20
- Vehicle: Water for Injection Q.S.
Product Specification
| Feature | Details |
| Active Molecule | Bevacizumab |
| Therapeutic Class | Antineoplastic / Monoclonal Antibody |
| Strength | 400 mg / 16 mL |
| Route of Administration | Intravenous (IV) Infusion |
| Vial Type | Single-use glass vial |
| Storage Requirement | Refrigerated at 2°C to 8°C; Do not freeze |
Mechanism of Action
- Binds specifically to the Vascular Endothelial Growth Factor (VEGF) protein, preventing it from interacting with its receptors on the surface of endothelial cells.
- Inhibits angiogenesis, the process by which tumors develop their own blood supply, effectively "starving" the cancer cells.
- Reduces microvascular permeability and lowers interstitial fluid pressure within the tumor, which may enhance the delivery of concurrent chemotherapy drugs.
- Promotes tumor regression by inducing the collapse of existing abnormal tumor vasculature.
Key Benefits
- Extended Survival: Proven to increase progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal and lung cancers.
- Precision Oncology: Acts as a targeted cancer treatment, focusing specifically on the biological pathways of tumor growth rather than affecting all rapidly dividing cells.
- Versatile Combinations: Synergizes effectively with various cytotoxic chemotherapy regimens to enhance the total therapeutic response.
- Disease Stabilization: Helps in controlling the spread of metastatic disease, providing better quality of life and symptom management for advanced-stage patients.
- Broad Spectrum: Effective across multiple indications, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma.
Precautions
| Condition or Situation | Precaution |
|---|---|
| Surgery or wound healing | Avoid use around surgery as it may delay wound healing |
| Bleeding disorders | Use carefully due to increased risk of bleeding |
| High blood pressure | Monitor closely as it may increase blood pressure |
| Kidney problems | Use with caution and monitor kidney function regularly |
| Pregnancy | Not recommended due to risk of harm to the unborn baby |
| Breastfeeding | Avoid use as it may pass into breast milk |
| Heart disease | Careful monitoring required in patients with cardiac conditions |
| Infections | Use cautiously as it may affect immune response |
| Gastrointestinal issues | May increase risk of GI perforation in susceptible patients |
| Elderly patients | Require closer monitoring for side effects |
Important Safety Information
- Use Cizumab Injection only under specialist supervision
- Regular monitoring of blood pressure and kidney function is required
- Report any unusual bleeding, severe headache, or chest pain immediately
- Do not use before or after surgery unless advised by a healthcare professional
- Follow all oncology treatment schedules strictly
Usage
Cizumab 400mg Injection is a sophisticated oncology medication that must be administered under the strict supervision of a qualified oncologist. As a VEGF inhibitor, its application is highly specific to the patient's clinical profile and the type of malignancy being treated.
Administration Steps
Professional Administration: This anticancer therapy is strictly for intravenous (IV) infusion and should never be administered as an IV push or bolus.
Preparation: The Bevacizumab solution must be diluted with 0.9% Sodium Chloride Injection by a healthcare professional in a sterile environment.
Infusion Timeline: The initial dose is typically delivered over 90 minutes. If well-tolerated, subsequent infusions may be shortened to 60 or 30 minutes.
Monitoring: Vital signs and infusion reactions are closely monitored by medical staff throughout the procedure.
Storage Handling: Vials should be kept in the original carton to protect from light and must be stored in a cold chain (2°C to 8°C) until the moment of preparation.
Surgical Precaution: Treatment should be suspended at least 28 days prior to and following major surgery to ensure proper wound healing.
Uses
Metastatic Colorectal Cancer (mCRC): Used as a first or second-line cancer treatment in combination with fluoropyrimidine-based chemotherapy.
Non-Small Cell Lung Cancer (NSCLC): Indicated for the treatment of unresectable, locally advanced, or metastatic non-squamous lung cancer.
Glioblastoma: Employed as a single agent for adults with progressive brain cancer following prior therapy.
Metastatic Renal Cell Carcinoma (mRCC): Used in combination with interferon-alfa to treat advanced kidney cancer.
Cervical and Ovarian Cancer: Targeted for patients with persistent, recurrent, or metastatic stages of these gynecological cancers.
Metastatic Breast Cancer: In specific regions, it is used alongside taxane chemotherapy for patients who have not received prior treatment for metastatic disease.
Side Effects
Common Side Effects
- High blood pressure during treatment
- Weakness and fatigue
- Nausea or vomiting
- Loss of appetite
- Mild headache or dizziness
Less Common Side Effects
- Nosebleeds or minor bleeding
- Protein in urine (proteinuria)
- Slow wound healing
- Diarrhea or abdominal discomfort
- Joint or muscle pain
Rare Side Effects
| Rare Side Effect | Description |
|---|---|
| Severe bleeding | May cause internal or life threatening bleeding |
| Gastrointestinal perforation | Rare tearing in stomach or intestinal wall |
| Blood clots | May increase risk of stroke or deep vein thrombosis |
| Severe allergic reaction | May include swelling, rash, or breathing difficulty |
| Heart complications | Rare risk of heart failure or cardiac issues |
| Severe infection risk | Reduced immune response may lead to serious infections |
Important Safety Information
- Regular monitoring is essential during treatment
- Report any bleeding, chest pain, or severe abdominal pain immediately
- Use only under specialist oncology supervision
- Do not ignore signs of infection or unusual swelling
FAQs
Q: What is Cizumab Injection used for?
A: Cizumab Injection is used in the treatment of various cancers including colorectal cancer, non-small cell lung cancer, cervical cancer, and renal cell carcinoma (kidney cancer). It is often used in combination with other chemotherapy medicines.
Q: How does Cizumab Injection work?
A: Cizumab contains Bevacizumab, a monoclonal antibody that works by blocking a protein called VEGF (Vascular Endothelial Growth Factor). This prevents the formation of new blood vessels that supply nutrients to tumours, helping to slow or stop cancer growth.
Q: How is Cizumab Injection administered?
A: Cizumab is administered as an intravenous (IV) infusion by a trained healthcare professional in a hospital or clinical setting. It is never self-administered at home.
Q: How often is Cizumab Injection given?
A: The dosage and frequency of Cizumab depends on the type of cancer being treated and the treatment protocol prescribed by your oncologist. It is typically given every 2 to 3 weeks.
Q: What are the common side effects of Cizumab Injection?
A: Common side effects include high blood pressure, fatigue, loss of appetite, headache, nausea, and increased risk of bleeding. Inform your doctor immediately if you experience any unusual symptoms.
Q: Can Cizumab Injection cause serious side effects?
A: Yes, in some cases Cizumab may cause serious side effects such as gastrointestinal perforation, severe bleeding, blood clots, impaired wound healing, and proteinuria (protein in urine). Regular monitoring by your doctor is essential during treatment.
Q: Who should not receive Cizumab Injection?
A: Cizumab should not be given to patients with uncontrolled high blood pressure, recent history of bleeding, upcoming surgery, or those who are pregnant or breastfeeding. Your oncologist will assess your suitability before starting treatment.
Q: Can Cizumab Injection be used during pregnancy?
A: No. Cizumab is not recommended during pregnancy as it may harm the unborn baby. Women of childbearing age should use effective contraception during treatment and for several months after the last dose.
Q: Will Cizumab Injection affect my ability to have surgery?
A: Yes. Bevacizumab can impair wound healing, so treatment is usually paused before and after any surgical procedure. Always inform your surgeon and oncologist if you are receiving Cizumab.
Interactions
| Interacting medicine or condition | Possible interaction effect |
|---|---|
| Other anti cancer therapies | May increase risk of severe side effects |
| NSAIDs (painkillers) | May increase risk of bleeding |
| Anticoagulants (blood thinners) | Higher risk of bleeding complications |
| Antihypertensive medicines | May affect blood pressure control |
| Corticosteroids | May increase infection risk when used together |
| Live vaccines | May increase risk of infection |
| Surgery or wound healing drugs | May delay wound healing and recovery |
| Kidney affecting medicines | May increase risk of kidney damage |
| Proteinuria causing drugs | May worsen protein loss in urine |
Important Interaction Advice
- Inform your oncology specialist about all medicines being used
- Avoid starting new medicines without medical approval
- Monitor blood pressure regularly during treatment
- Report any bleeding, swelling, or unusual symptoms immediately
- Follow strict medical supervision during combination cancer therapy
| Manufacturer | : | Hetero Pharma, India |
| Trade Name | : | Avastin |
| Generic Search | : | Bevacizumab |
| Strength | : | 400mg |
Latest Products
